AfatinibVarious toxicities and drug resistance following off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1880卷 / 1期

关键词：

D O I：

10.1007/s40278-021-04856-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：22 / 22

相关论文

共 50 条

[1] CannabidiolVarious toxicities following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1860 (1) : 103 - 103
[2] GuselkumabVarious toxicities following off-label treatment: case report
[J]. Reactions Weekly, 2022, 1908 (1) : 264 - 264
[3] OsimertinibVarious toxicities following off-label treatment: case report
[J]. Reactions Weekly, 2018, 1724 (1) : 285 - 285
[4] Immunosuppressants/rituximabVarious toxicities following an off-label treatment: case report
[J]. Reactions Weekly, 2022, 1924 (1) : 251 - 251
[5] TrametinibAcquired drug resistance with off-label treatment: case report
[J]. Reactions Weekly, 2019, 1774 (1) : 298 - 298
[6] KetamineVarious toxicities following overdose of off-label drug use: case report
[J]. Reactions Weekly, 2023, 1976 (1) : 188 - 188
[7] AntineoplasticsVarious toxicities and acquired resistance following off-label use: case report
[J]. Reactions Weekly, 2021, 1843 (1) : 48 - 48
[8] ErtapenemAcquired drug resistance following off-label use: case report
[J]. Reactions Weekly, 2022, 1909 (1) : 245 - 245
[9] Hydrocortisone/methylprednisolone/tocilizumabVarious toxicities following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1848 (1) : 199 - 199
[10] LenvatinibVarious toxicities following off-label use: case report
[J]. Reactions Weekly, 2021, 1851 (1) : 202 - 202

← 1 2 3 4 5 →